After One-Off Cash Infusions, YZY Biopharma Looks for More Funds From IPO 轉讓管線出售股權“補血” 友芝友生物待上市自救
The cash-challenged biotech firm specializing in BsAbs and immuno-oncology therapies is turning to a Hong Kong listing to try to replenish its coffers. 這間深耕雙抗靶向和腫瘤免疫療法開發的生物科技公司財政緊絀，已向港交所申請上市籌資。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.